All News
Different Autoantibody Phenotypes in Juvenile and Adult Myositis
A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.
Read ArticleIncreasing Incidence of Morphea
A large EMR derived cohort study of over 10,000 patients with morphea (localized scleroderma) sheds light on its prevalence and associated features.
Read ArticleLinger on the Fingers (9.6.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week with a focus on fingers and better prescriptive follow through.
Read ArticleCAR-T Like Effects with Bispecific Teclistamab
A new chapter may have begun in the exciting story of "immune reset" therapy for difficult-to-treat autoimmune diseases, with a patient with severe refractory lupus obtaining drug-free remission after treatment with an antibody product normally used in multiple myeloma.
Read ArticleScleroderma Raynaud's May Worsen in Summer
Episodes of Raynaud's phenomenon, a common feature of systemic sclerosis (SSc, also known as scleroderma), were more severe not only at low temperatures, as one would expect, but also during summertime heat, a multinational study found.
Read ArticleSustained Hydroxychloroquine and Cardiovascular Outcomes
A national cohort study shows that continuous use of hydroxychloroquine (HCQ) protects agains cardiovascular (CV) events in patients with systemic lupus erythematosus (SLE).
Read ArticleRunning with Data (8.30.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com - including tips on steroids, MAS, and myositis testing.
Read ArticleBirth Control Use in Lupus
Published guidelines on lupus management urge that female patients plan and prepare carefully for pregnancy, and use contraceptives when it's not intended -- but these recommendations are only rarely followed, a registry study suggested.
Read Article
Dr. John Cush RheumNow ( View Tweet)


